- Home
- XTKG vs SYBX Comparison
XTKG vs SYBX Comparison
Compare XTKG & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTKG
- SYBX
- Stock Information
- Founded
- XTKG 1997
- SYBX N/A
- Country
- XTKG Singapore
- SYBX United States
- Employees
- XTKG 178
- SYBX N/A
- Industry
- XTKG
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- XTKG
- SYBX Health Care
- Exchange
- XTKG NYSE
- SYBX Nasdaq
- Market Cap
- XTKG 16.3M
- SYBX 13.6M
- IPO Year
- XTKG 2019
- SYBX N/A
- Fundamental
- Price
- XTKG $1.30
- SYBX $1.11
- Analyst Decision
- XTKG
- SYBX
- Analyst Count
- XTKG 0
- SYBX 0
- Target Price
- XTKG N/A
- SYBX N/A
- AVG Volume (30 Days)
- XTKG 306.5K
- SYBX 11.1K
- Earning Date
- XTKG 05-27-2025
- SYBX 05-20-2025
- Dividend Yield
- XTKG N/A
- SYBX N/A
- EPS Growth
- XTKG N/A
- SYBX N/A
- EPS
- XTKG N/A
- SYBX 0.21
- Revenue
- XTKG $11,611,442.00
- SYBX N/A
- Revenue This Year
- XTKG N/A
- SYBX N/A
- Revenue Next Year
- XTKG N/A
- SYBX N/A
- P/E Ratio
- XTKG N/A
- SYBX $5.25
- Revenue Growth
- XTKG N/A
- SYBX N/A
- 52 Week Low
- XTKG $0.08
- SYBX $0.90
- 52 Week High
- XTKG $2.14
- SYBX $1.91
- Technical
- Relative Strength Index (RSI)
- XTKG 52.33
- SYBX 45.72
- Support Level
- XTKG $0.62
- SYBX $1.05
- Resistance Level
- XTKG $2.22
- SYBX $1.19
- Average True Range (ATR)
- XTKG 0.29
- SYBX 0.09
- MACD
- XTKG 0.03
- SYBX 0.00
- Stochastic Oscillator
- XTKG 42.50
- SYBX 55.00
About XTKG X3 HOLDINGS CO LTD
X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries. It generates revenue from service lines: Application development services; Consulting and technical support services; Subscription services; Trading; and Others, of which maximum revenue is derived from Application development services. Geographically, all of the company's revenue is derived from PRC.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.